(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
1 September 2011 (01.09.2011)

PCT

(10) International Publication Number
WO 2011/106478 A2

(51) International Patent Classification:
A61K 9/20 (2006.01)

(21) International Application Number:
PCT/US2011/025994

(22) International Filing Date:
24 February 2011 (24.02.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/308,056 25 February 2010 (25.02.2010) US

(71) Applicants *(for all designated States except US)*: **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; Rt. 206 & Province Line Road, Princeton, NJ 08543-4000 (US). **PFIZER INC.** [US/US]; 234 East 42nd Street, New York, NY 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **PATEL, Jatin** [US/US]; c/o Bristol-Myer Squibb Company, 1 Squibb Drive, New Brunswick, NJ 08903 (US). **FROST, Charles** [US/US]; c/o Bristol-Myer Squibb Company, Route 206 And Province Line Road, Princeton, NJ 08543 (US). **JIA, Jingpin** [US/US]; c/o Bristol-Myer Squibb Company, 1 Squibb Drive, New Brunswick, NJ 08903 (US). **VEMAVARAPU, Chandra** [IN/US]; c/o Bristol-Myer Squibb Company, 1 Squibb Drive, New Brunswick, NJ 08903 (US).

(74) Agents: **OKUN, Jason, M.** et al.; Fitzpatrick, Cella, Harper & Scinto, 1290 Avenue Of The Americas, New York, NY 10104-3801 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: APIXABAN FORMULATIONS

Figure 3: Dissolution Rates of 2.5-mg Apixaban Tablets Using Drug Substance of Different Particle Size



(57) Abstract: Compositions comprising crystalline apixaban particles having a D_{90} equal to or less than 89 μm, and a pharmaceutically acceptable carrier, are substantially bioequivalent and can be used to for the treatment and/or prophylaxis of thromboembolic disorders.

WO 2011/106478 A2

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*